Transcatheter Closure of Patent Foramen Ovale: Randomized Trial Update

Angelos Arfaras-Melainis, Leonidas Palaiodimos, Mohammad K. Mojadidi

Research output: Contribution to journalReview article

Abstract

A patent foramen ovale (PFO) is found in about one-quarter of all adults, but the prevalence increases to approximately half of those with a history of a so-called cryptogenic stroke. The true efficacy of PFO closure for prevention of recurrent paradoxical embolism has been debated for years, as the early 3 randomized trials did not show a statistically significant benefit of PFO closure over standard-of-care medical therapy. However, 3 recent randomized trials along with the long-term follow-up data from the largest early trial demonstrated superiority of device closure for secondary stroke prevention.

Original languageEnglish (US)
JournalInterventional Cardiology Clinics
DOIs
StatePublished - Jan 1 2019

Fingerprint

Patent Foramen Ovale
Stroke
Paradoxical Embolism
Standard of Care
Secondary Prevention
Equipment and Supplies
Therapeutics

Keywords

  • Cryptogenic stroke
  • Embolic stroke of undetermined source
  • ESUS
  • PFO
  • PFO closure
  • Stroke prevention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Transcatheter Closure of Patent Foramen Ovale : Randomized Trial Update. / Arfaras-Melainis, Angelos; Palaiodimos, Leonidas; Mojadidi, Mohammad K.

In: Interventional Cardiology Clinics, 01.01.2019.

Research output: Contribution to journalReview article

@article{85f0ea05054e479a8af7796b3607c759,
title = "Transcatheter Closure of Patent Foramen Ovale: Randomized Trial Update",
abstract = "A patent foramen ovale (PFO) is found in about one-quarter of all adults, but the prevalence increases to approximately half of those with a history of a so-called cryptogenic stroke. The true efficacy of PFO closure for prevention of recurrent paradoxical embolism has been debated for years, as the early 3 randomized trials did not show a statistically significant benefit of PFO closure over standard-of-care medical therapy. However, 3 recent randomized trials along with the long-term follow-up data from the largest early trial demonstrated superiority of device closure for secondary stroke prevention.",
keywords = "Cryptogenic stroke, Embolic stroke of undetermined source, ESUS, PFO, PFO closure, Stroke prevention",
author = "Angelos Arfaras-Melainis and Leonidas Palaiodimos and Mojadidi, {Mohammad K.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.iccl.2019.05.002",
language = "English (US)",
journal = "Interventional Cardiology Clinics",
issn = "2211-7458",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Transcatheter Closure of Patent Foramen Ovale

T2 - Randomized Trial Update

AU - Arfaras-Melainis, Angelos

AU - Palaiodimos, Leonidas

AU - Mojadidi, Mohammad K.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - A patent foramen ovale (PFO) is found in about one-quarter of all adults, but the prevalence increases to approximately half of those with a history of a so-called cryptogenic stroke. The true efficacy of PFO closure for prevention of recurrent paradoxical embolism has been debated for years, as the early 3 randomized trials did not show a statistically significant benefit of PFO closure over standard-of-care medical therapy. However, 3 recent randomized trials along with the long-term follow-up data from the largest early trial demonstrated superiority of device closure for secondary stroke prevention.

AB - A patent foramen ovale (PFO) is found in about one-quarter of all adults, but the prevalence increases to approximately half of those with a history of a so-called cryptogenic stroke. The true efficacy of PFO closure for prevention of recurrent paradoxical embolism has been debated for years, as the early 3 randomized trials did not show a statistically significant benefit of PFO closure over standard-of-care medical therapy. However, 3 recent randomized trials along with the long-term follow-up data from the largest early trial demonstrated superiority of device closure for secondary stroke prevention.

KW - Cryptogenic stroke

KW - Embolic stroke of undetermined source

KW - ESUS

KW - PFO

KW - PFO closure

KW - Stroke prevention

UR - http://www.scopus.com/inward/record.url?scp=85069656710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069656710&partnerID=8YFLogxK

U2 - 10.1016/j.iccl.2019.05.002

DO - 10.1016/j.iccl.2019.05.002

M3 - Review article

AN - SCOPUS:85069656710

JO - Interventional Cardiology Clinics

JF - Interventional Cardiology Clinics

SN - 2211-7458

ER -